Skip to main content

Bonesupport Holding AB (publ) (0RQO.L)

London Stock Exchange Healthcare Medical - PharmaceuticalsView data quality →
54.9Fair

ValueMarkers Composite Index

Top 52%#21,256 of 44,707

DCF data not available

Piotroski
6/9
Neutral
Beneish
-2.60
Low Risk
Altman
56.09
Safe
DCF Value
-
N/A
ROIC
19.1%
Strong
P/E
109.3
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Bonesupport Holding AB (publ) (0RQO.L) — VMCI valuation read

0RQO.L screens at VMCI 55/100, a 5-point gap above the Healthcare sector median (50). For a mid-cap Bonesupport Holding AB (publ) share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

0RQO.L has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: 0RQO.L trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 3.3x is the binding constraint on the bear case, which sets the rate-cycle exposure for Bonesupport Holding AB (publ).

0RQO.L rose 0.3% over the trailing 7 days, with a +2.6% read on a 30-day basis.

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.

CEO: Torbjorn Skold140 employeesSEwww.bonesupport.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 0RQO.L’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.